Back to top
more

Inovio Pharmaceuticals (INO)

(Delayed Data from NSDQ)

$5.54 USD

5.54
207,804

+0.02 (0.36%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $5.55 +0.01 (0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth

by Zacks Equity Research

Inovio (INO) focuses on the development of its most advanced candidate, VGX-3100 vaccine, which has been progressing well. Its collaboration with big pharma companies exhibits strong growth.

    Inovio Initiates Dosing in Phase I/IIa Study on MERS Vaccine

    by Zacks Equity Research

    Inovio Pharmaceuticals (INO) administers dosage in the first patient under a phase I/IIa trial to assess its MERS vaccine INO-4700.

      Inovio (INO) Initiates Phase I Study on Hepatitis C Vaccine

      by Zacks Equity Research

      Inovio Pharmaceuticals (INO) and Korean partner GeneOne Life Science dose the first patient in a phase I study, which will assess its hepatitis C vaccine GLS-6150.

        Inovio Pharmaceuticals Initiates Dosing in HIV Vaccine Study

        by Zacks Equity Research

        Inovio Pharmaceuticals (INO) doses the first patient in a phase I/II study, which will evaluate its HIV vaccine Pennvax-GP's ability to bring about remission of HIV.

          Inovio (INO) Q2 Loss Narrows, Revenues Surpass Estimates

          by Zacks Equity Research

          Inovio's (INO) Q2 loss betters estimates. Also, the company rides high on revenue beat.

            Inovio Pharmaceuticals (INO) Reports Q2 Loss, Tops Revenue Estimates

            by Zacks Equity Research

            Inovio (INO) delivered earnings and revenue surprises of 77.14% and 1050.54%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

              What's in the Cards for Inovio (INO) This Earnings Season?

              by Zacks Equity Research

              During Inovio's (INO) second-quarter 2018 earnings call, investor focus will remain on the company's progress with its lead candidate VGX-3100.

                Inovio (INO) Down 5.8% Since Earnings Report: Can It Rebound?

                by Zacks Equity Research

                Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  Inovio Pharmaceuticals (INO) in Focus: Stock Moves 5.7% Higher

                  by Zacks Equity Research

                  Inovio Pharmaceuticals (INO) was a big mover last session, as the company saw its shares rise nearly 6% on the day.

                    What's in the Cards for Inovio (INO) This Earnings Season?

                    by Zacks Equity Research

                    Inovio's (INO) most advanced pipeline candidate, VGX-3100's progress remains in focus. However, lack of an approved product in the company's portfolio is a dampener.

                      Why Is Inovio (INO) Up 6.6% Since Its Last Earnings Report?

                      by Zacks Equity Research

                      Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                        What's in the Cards for Inovio (INO) This Earnings Season?

                        by Zacks Equity Research

                        Inovio's (INO) most advanced pipeline candidate, VGX-3100's consistent progress might drive the stock in Q4. However, lack of an approved product in the company's portfolio is a dampener.

                          Inovio's Influenza Vaccine Shows Potential, Shares Rally

                          by Zacks Equity Research

                          Inovio Pharmaceuticals' (INO) universal influenza vaccine leads to broad protective antibody responses against all major deadly strains of H1 virus.

                            Benjamin Rains headshot

                            3 Stocks Under $10 That Surged Today

                            by Benjamin Rains

                            Here at Zacks, we encourage investors to follow our proven stock-picking system, which places a great deal of emphasis on the importance of earnings estimate revisions in order to identify winning stocks. However, we also always look to cover stocks, from S&P 500 powers to small cap-firms, when they make newsworthy moves.

                              Inovio Amends Chinese Deal for Immunotherapy, Shares Up

                              by Zacks Equity Research

                              Inovio (INO) entered into an amended agreement with ApolloBio Corporation and grants ApolloBio the exclusive right to develop and commercialize VGX-3100 within Greater China.

                                Inovio (INO) Down 15.5% Since Earnings Report: Can It Rebound?

                                by Zacks Equity Research

                                Inovio (INO) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                  What's in the Cards for Merck KGaA (MKGAF) in Q3 Earnings?

                                  by Zacks Equity Research

                                  Merck's (MKGAF) Healthcare and Life Science segments are expected to drive third-quarter sales. The company is progressing with its oncology drug, Bavencio and is also focusing on streamlining its business.

                                    5 Biotech Stocks Well Poised to Surpass Expectations in Q3

                                    by Zacks Equity Research

                                    The pharma and biotech industry has demonstrated strength

                                      Puma (PBYI) Q3 Earnings: Will it Surpass Estimates Again?

                                      by Zacks Equity Research

                                      Puma Biotechnology's (PBYI) only marketed product, Nerlynx (neratinib), for advanced breast cancer was launched in August. So Q3 is the first quarter in which Puma will record sales for Nerlynx.

                                        BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?

                                        by Zacks Equity Research

                                        BioDelivery Sciences (BDSI) has been focusing on growth territories and expanding Bunavail's label. However, the extent to which these impact third-quarter results remains to be seen.

                                          Inovio Initiates Bladder Cancer Study With Roche's Tecentriq

                                          by Zacks Equity Research

                                          Inovio Pharmaceuticals (INO) will evaluate a combination of checkpoint inhibitor and T cell activator as a potential treatment for advanced bladder cancer in a new early stage study.

                                            Surging Earnings Estimates Signal Good News for Inovio (INO)

                                            by Zacks Equity Research

                                            Inovio Pharmaceuticals (INO) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.

                                              Inovio (INO) Q2 Earnings: What Lies Ahead for the Stock?

                                              by Zacks Equity Research

                                              Inovio Pharmaceuticals' (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q2. However, lack of an approved product in portfolio is a dampener.

                                                Why Is Inovio (INO) Up 21.3% Since the Last Earnings Report?

                                                by Zacks Equity Research

                                                Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                  Inovio (INO) Stock Rises on Encouraging HIV Vaccine Data

                                                  by Zacks Equity Research

                                                  Inovio Pharmaceuticals Inc. (INO) shares have rallied 12% since the company announced that its HIV vaccine evoked almost 100% immune response rates in a clinical study